NGM Overview

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.

Wall Street analysts forecast NGM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NGM Biopharmaceuticals Inc revenue for the last quarter amounts to 165.00K USD, decreased -99.09 % YoY.

NGM Biopharmaceuticals Inc. EPS for the last quarter amounts to -0.33 USD, decreased -26.67 % YoY.

NGM Biopharmaceuticals Inc (NGM) has 138 emplpoyees as of January 17 2026.

Today NGM has the market capitalization of 128.53M USD.